Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Liver Cancer
Interventions
DRUG

Sunitinib Malate

Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00495625 - Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) | Biotech Hunter | Biotech Hunter